Search

Displaying results 1421 - 1430 of 1613 in total
  1. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40754] It provides a treatment option for patients who have MF with severe thrombocytopenia, which occurs in approximately one-third of MF patients and carries with it a particularly poor prognosis.

  2. Drug

    Danegaptide

    go.drugbank.com/drugs/DB11821
    Investigational

    Danegaptide has been investigated for the treatment of Focus of Study is STEMI.

  3. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

  4. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.

  5. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema. Ecallantide is a recombinant 60-amino-acid protein produced in Pichia pastoris yeast cells ...

  6. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO

  7. Drug

    Pentaerythritol tetranitrate

    go.drugbank.com/drugs/DB06154
    ApprovedWithdrawn

    It is also one of the most powerful high explosives known and is a component of the plastic explosive known as Semtex [L2393]. PETN has the chemical formula C5H8N4O12.

  8. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    Lipegfilgrastim, previously known as XM22, is a pegylated, recombinant granulocyte colony-stimulating factor (G-CSF) that was synthetized using a highly site-specific glycoPEGylation technology [A32665

  9. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure lability and other cardiovascular side effects - for this reason, these medications are less

  10. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy.